Purdue Pharma LP is relying on the US FDA's opioid labeling decisions to squash a suit by the Commonwealth of Massachusetts alleging it improperly marketed its opioid medications for long-term therapy at high doses.
The company cites FDA approval of its OxyContin (oxycodone), Butrans (buprenorphine) transdermal system, and Hysingla (hydrocodone) extended release/long-acting opioid analgesics...





